Table 3 Prevalence of co-morbidity and multi-morbidity stratified by patient characteristics
Variable | Co-morbidity prevalence (number of events) | Multi-morbidity prevalence (number of events) |
|---|---|---|
Age groups | ||
 18–≤35 years | 12.4 (30) | 0.4 (1) |
 35–≤45 years | 16.3 (66) | 2.5 (10) |
 45–≤55 years | 21.8 (54) | 5.7 (14) |
 >55 years | 38.1 (51) | 16.4 (22) |
 p value | 0.000 | 0.000 |
Gender | ||
 Male | 47 (14.9) | 2.9 (9) |
 Female | 156 (21.8) | 5.4 (38) |
 p value | 0.010 | 0.025 |
Baseline CD4+ cell counts (cells/mL) | ||
 <350 | 142 (20.1) | 5.0 (34) |
 ≥350 | 23 (18.3) | 4.0 (5) |
 p value | 0.535 | 0.877 |
ART duration | Â | Â |
 <2 years | 20.1 (38) | 4.4 (8) |
 2–5 years | 18.3 (48) | 4.2 (11) |
 >5 years | 20.5 (115) | 4.7 (26) |
 p value | 0.730 | 0.88 |
ART regimen | ||
 PI-based | 20.4 (10) | 0.0 (0) |
 D4T/3TC + EFV or NVP | 20.3 (127) | 4.8 (30) |
 TDF/3TC + EFV or NVP | 31.7 (39) | 10.7 (10) |
 AZT/3TC + EFV or NVP | 23.5 (27) | 3.5 (4) |
 p value | 0.471 | 0.244 |